Dr. Apolo on Immunotherapy Combinations With Cabozantinib in Genitourinary Tumors

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses immunotherapy combinations with cabozantinib (Cometriq) in genitourinary tumors.

In a phase I study, cabozantinib plus nivolumab (Opdivo), as well as cabozantinib/nivolumab plus ipilimumab (Yervoy) was evaluated in patients with refractory metastatic urothelial carcinoma and other genitourinary tumors.

Apolo reports that the overall response rate for the entire cohort is 37%, while the bladder cancer cohort is 44%.